Biospherics.net Inc. was launched in 2013 as a scientific research company. The company is focused on biological and pharmaceutical research as well as information technology.
Biospherics is a leader in the application of combination drugs to complex diseases, molecular simulations and modeling, and research in the metabolic syndrome. The Company’s newest lead candidates are BSN908 for treatment of abdominal aortic aneurysm, and BSN272, for reducing triglycerides, cholesterol and atherosclerosis. Biospherics also has phase 3 clinical trial results with BSN175, being developed as an oral treatment for glycemic control in patients with metabolic syndrome and diabetes.
Biospherics.net has not received any reviews.
Biospherics.net has not received any endorsements.